知镜 Cognispect · 医学文献与研究工作台

The Hsd17b13 P260S patient variant knock-in male mouse model provides translational insights into HSD17B13 biology.

Slabber CF, Lenkeit F, Grove K, Aebi A, Orsini V, Reyes A, Ludwig V, Crochemore C, Bergling S, Wild S, Naumann U, Enos K, Abrams AS, Zeller H, Bhol R, Wang L, Redmond E, Wetzel K, Capodieci P, Heikelä H, Martinez-Nieto G, Mairinoja L, Sipilä P, Strauss L, Baumgarten BU, George EL, Heim M, Terracciano L, Bouwmeester A, Tchorz JS, Poutanen M, Ruffner H, Bordoli MR.
EBioMedicine · 2026-08-14 · PMID 42600259

文献摘要

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent liver disease that can progress to metabolic dysfunction-associated steatohepatitis (MASH), a condition marked by inflammation and fibrosis that increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma. Loss-of-function (LoF) variants of hydroxysteroid 17-β dehydrogenase 13 (HSD17B13), a lipid droplet-associated enzyme, protect against progression from MASLD to MASH and more severe types of liver disease. Methods We generated a knock-in mouse model harbouring the human orthologue of the HSD17B13 P260S patient variant and investigated the molecular mechanisms underlying its protective phenotype upon dietary challenge, by applying comprehensive spatial transcriptomics, histological analysis, matrix-assisted laser desorption/ionisation (MALDI) imaging, and in vitro cellular characterisation. Findings Male Hsd17b13 P260S mice showed reduced liver fibrosis (p P260S mice showed increased steatosis (p P260S compared to WT upon HTF feeding. Interpretation Our study suggests that the Hsd17b13 P260S mouse model is translatable towards human physiology and useful for understanding the protective mechanisms of the human HSD17B13 P260S LoF variant. Lower HSD17B13 P260S protein abundance, reduced enzymatic activity and retained periportal localisation may contribute to protection from liver disease progression by maintaining zonated transcriptomic and lipidomic profiles. These findings provide key insights into HSD17B13 biology and its role in MASLD to MASH progression. Funding Novartis Biomedical Research Postdoctoral program, Sigrid Jusélius Foundation, Forendo Pharma.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。